Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.


Journal

European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 22 05 2019
accepted: 01 07 2019
revised: 17 06 2019
pubmed: 3 8 2019
medline: 11 3 2020
entrez: 3 8 2019
Statut: ppublish

Résumé

To determine the diagnostic accuracy and predictive value of gadoxetic acid liver MRI (Gd-EOB-DTPA MRI) alone or in combination with diffusion-weighted imaging (DWI) as a second-line tool for detecting early hepatocellular carcinoma (HCC) recurrence in cirrhotic patients with previous HCC treated with resection or ablation. Between 2014 and 2017, we prospectively included 34 cirrhotic patients with complete response to resection and/or ablation of early HCC in whom a new focal lesion enhancing in the arterial phase without washout was detected during follow-up with EC-MRI. After signing the informed consent, all patients underwent DWI and Gd-EOB-DTPA MRI; two readers analyzed signal intensities on each phase of dynamic study and on DWI. The final diagnosis was established by histology or follow-up EC-MRI. We used cross-tabulation to calculate indices of diagnostic accuracy. We evaluated 34 patients (7 women; 73.5% with hepatitis C virus) with a total of 53 new arterial-phase-enhancing foci (median size, 10 [IQR 9-14] mm). The final diagnosis, reached by histopathology in 15 (35.7%) lesions and EC-MR follow-up in 27 (64.3%), was HCC in 42 (79.2%) and benign conditions in 11 (21.8%). Hepatobiliary-phase hypointensity on Gd-EOB-DTPA MRI plus hyperintensity on DWI yielded 54.8% sensitivity, 90.9% specificity, 95.8% positive predictive value, and 34.5% negative predictive value for diagnosing HCC recurrence. Among potential indices, combining hypointensity on hepatobiliary-phase Gd-EOB-DTPA MRI and hyperintensity on DWI has the highest specificity and positive predictive value to optimally detect HCC recurrence prior to confident diagnosis by conventional imaging criteria on EC-MRI in cirrhotic liver. • In patients at risk of HCC recurrence, the use of gadoxetic acid liver MRI and DWI may improve the differentiation of unspecific new arterial-enhancing foci from early hypervascular HCC recurrence in patients with non-conclusive findings on extracellular liver MRI. • Combined findings on hepatobiliary-phase gadoxetic acid-enhanced liver MRI and DWI had high specificity (90.9%) and positive predictive value (95.8%) for detecting early hypervascular HCC recurrence, but limited sensitivity. • Combining hepatobiliary-phase hypointensity on gadoxetic acid MRI and hyperintensity on diffusion-weighted imaging allows early diagnosis of hypervascular hepatocellular carcinoma and may help select patients for salvage therapy.

Identifiants

pubmed: 31372783
doi: 10.1007/s00330-019-06351-0
pii: 10.1007/s00330-019-06351-0
doi:

Substances chimiques

Contrast Media 0
gadolinium ethoxybenzyl DTPA 0
Gadolinium DTPA K2I13DR72L

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

186-194

Références

Poon RT, Fan ST, Lo CM, Liu CL, Wong J (2002) Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function. Ann Surg 235:373–382
doi: 10.1097/00000658-200203000-00009
Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S (2015) Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 261:947–955
doi: 10.1097/SLA.0000000000000710
Sala M, Llovet JM, Vilana R et al (2004) Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 40:1352–1360
doi: 10.1002/hep.20465
European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69:182–236
doi: 10.1016/j.jhep.2018.03.019
Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750
doi: 10.1002/hep.29913
Forner A, Vilana R, Ayuso C et al (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47:97–104
doi: 10.1002/hep.21966
Sangiovanni A, Manini MA, Iavarone M et al (2010) The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 59:638–644
doi: 10.1136/gut.2009.187286
Khalili K, Kim TK, Jang H-J et al (2011) Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 54:723–728
doi: 10.1016/j.jhep.2010.07.025
Joo I, Lee JM, Lee DH, Jeon JH, Han JK, Choi BI (2015) Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur Radiol 25:2859–2868
doi: 10.1007/s00330-015-3686-3
Granito A, Galassi M, Piscaglia F et al (2013) Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the noninvasive diagnosis of small hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther 37:355–363
doi: 10.1111/apt.12166
Haradome H, Unno T, Morisaka H et al (2017) Gadoxetic acid disodium-enhanced MR imaging of cholangiolocellular carcinoma of the liver: imaging characteristics and histopathological correlations. Eur Radiol 27:4461–4471
doi: 10.1007/s00330-017-4811-2
Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430
doi: 10.1016/S0168-8278(01)00130-1
Tremosini S, Forner A, Boix L et al (2012) Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut 61:1481–1487
doi: 10.1136/gutjnl-2011-301862
International Consensus Group for Hepatocellular Neoplasia The International Consensus Group for Hepatocellular Neoplasia (2009) Pathologic diagnosis of early hepatocellular carcinoma: A report of the International Consensus Group for Hepatocellular Neoplasia. Hepatology 49:658–664
doi: 10.1002/hep.22709
Rimola J, Forner A, Tremosini S et al (2012) Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol 56:1317–1323
doi: 10.1016/j.jhep.2012.01.004
Iavarone M, Sangiovanni A, Forzenigo LV et al (2010) Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation. Hepatology 52:1723–1730
doi: 10.1002/hep.23903
Darnell A, Forner A, Rimola J et al (2015) Liver imaging reporting and data system with MR imaging: evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US. Radiology 275:141–132
doi: 10.1148/radiol.15141132
Choi JW, Lee JM, Kim SJ et al (2013) Hepatocellular carcinoma: imaging patterns on gadoxetic acid–enhanced MR images and their value as an imaging biomarker. Radiology 267:776–786
doi: 10.1148/radiol.13120775
Sugimoto K, Kim SR, Imoto S et al (2015) Characteristics of hypovascular versus hypervascular well-differentiated hepatocellular carcinoma smaller than 2 cm - focus on tumor size, markers and imaging detectability. Dig Dis 33:721–727
doi: 10.1159/000439078
Yoon JH, Lee JM, Kang H et al (2019) Quantitative assessment of liver function by using gadoxetic acid–enhanced MRI: hepatocyte uptake ratio. Radiology 290:125–133
doi: 10.1148/radiol.2018180753
Kim AY, Kim YK, Lee MW et al (2012) Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis. Acta Radiol 53:830–838
Nakamura Y, Tashiro H, Nambu J et al (2013) Detectability of hepatocellular carcinoma by gadoxetate disodium-enhanced hepatic MRI: tumor-by-tumor analysis in explant livers. J Magn Reson Imaging 37:684–691
doi: 10.1002/jmri.23855
Motosugi U, Ichikawa T, Sou H et al (2010) Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 256:151–158
doi: 10.1148/radiol.10091885

Auteurs

Jordi Rimola (J)

BCLC group, Radiology Department, Hospital Clínic Barcelona, Barcelona, Spain. jrimola@clinic.cat.
University of Barcelona, Barcelona, Spain. jrimola@clinic.cat.

Alejandro Forner (A)

University of Barcelona, Barcelona, Spain.
BCLC group, Liver Unit, Hospital Clínic Barcelona, Barcelona, Spain.
IDIBAPS, Barcelona, Spain.

Víctor Sapena (V)

IDIBAPS, Barcelona, Spain.
BCLC group, Statistics core, Barcelona, Spain.

Neus Llarch (N)

BCLC group, Liver Unit, Hospital Clínic Barcelona, Barcelona, Spain.

Anna Darnell (A)

BCLC group, Radiology Department, Hospital Clínic Barcelona, Barcelona, Spain.
University of Barcelona, Barcelona, Spain.

Alba Díaz (A)

BCLC group, Pathology Department, Hospital Clínic Barcelona, Barcelona, Spain.

Angeles García-Criado (A)

BCLC group, Radiology Department, Hospital Clínic Barcelona, Barcelona, Spain.
University of Barcelona, Barcelona, Spain.

Lluís Bianchi (L)

BCLC group, Radiology Department, Hospital Clínic Barcelona, Barcelona, Spain.
University of Barcelona, Barcelona, Spain.

Ramon Vilana (R)

BCLC group, Radiology Department, Hospital Clínic Barcelona, Barcelona, Spain.

Álvaro Díaz-González (Á)

BCLC group, Liver Unit, Hospital Clínic Barcelona, Barcelona, Spain.

Carmen Ayuso (C)

BCLC group, Radiology Department, Hospital Clínic Barcelona, Barcelona, Spain.
University of Barcelona, Barcelona, Spain.
IDIBAPS, Barcelona, Spain.

Jordi Bruix (J)

University of Barcelona, Barcelona, Spain.
BCLC group, Liver Unit, Hospital Clínic Barcelona, Barcelona, Spain.
IDIBAPS, Barcelona, Spain.

María Reig (M)

BCLC group, Liver Unit, Hospital Clínic Barcelona, Barcelona, Spain.
IDIBAPS, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH